Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab vs bisphosphonates in children and adolescents with osteogenesis imperfecta
2023-503294-37-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of romosozumab in osteogenesis imperfecta (OI) (2 arms), sponsored by Amgen. Primary endpoints: Number of clinical fractures through Month 12, Number of any fractures through Month 12 and 1 more. Planned start Oct 2023; status: authorised.
02
Drugs
romosozumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2023-503294-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503294-37-00.